Expert discusses expanding roster of options for dry eye disease

expert discusses expanding roster of options for dry eye disease

Sumary of Expert discusses expanding roster of options for dry eye disease:

  • Back to Healio NEW ORLEANS — Recent years have brought several significant advances in dry eye disease treatment, Amy Lin, MD, said during Cornea Subspecialty Day at the American Academy of Ophthalmology meeting.
  • New treatments for dry eye disease (DED) include novel mechanisms of action and delivery systems.
  • Amy Lin Lin discussed FDA-approved DED treatments including Eysuvis (loteprednol etabonate ophthalmic suspension 0.25%, Kala Pharmaceuticals), Tyrvaya (varenicline solution 0.03 mg, Oyster Point Pharma) and iTEAR100 (Olympic Ophthalmics).
  • Eysuvis, which was approved in October 2020 for short-term DED, uses proprietary Ampplify mucus-penetrating technology to improve symptoms and signs of DED, Lin said, noting that she mainly uses Eysuvis for acute dry eye flares, but that it can also be used for induction therapy when initiating chronic topical anti-inflammatory treatment.
  • “There are several novel existing and potential future treatments for dry eye disease,” Lin said.

Want to know more click here go to source.

From -

Close

Site Language


By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close